aurobindo pharma share price target
Barring weakness in API (-14% YoY), most markets grew at healthy pace. Currently, the shares of Aurobindo Pharma are trading at Rs 915 apiece, translating to a 31% upside. Entry. Check out why Aurobindo Pharm share price is falling today. Maintain BUY. Target price: Rs 1,200. In contrast to peers, Aurobindo's US business (ex-Natrol) performed well and grew 4% QoQ driven by volume gains and improvement in injectables revenues. Cardiac and anti-diabetic growth takes a breather in Jan-21 at 8.8% and 5.3% after reporting double digit growth in most months during lockdown. Aurobindo Pharma AUROPHARMA share price targets Levels of 937.78, 934.07, 907.06, 866.8, 813.68 are share price targets for Aurobindo Pharma AUROPHARMA Click here for weekly and monthly share price targets Experts also view these below mentioned levels as important because Aurobindo Pharma has been reversing its trend at these levels. Signal. AUROBINDO PHARMA LTD. Share/Stock Price - 524804 BSE INDIA Technical Analysis, Target, Important Levels, Latest News, Interactive Charts. Q3 revenue/PAT grew by 8%/17% YoY, in line with estimates. IPM is struggling for growth above 10% even after MoM abating COVID concerns and with MRs, physician activities almost reaching pre-COVID level. In rupee terms, US sales have grown at 17% CAGR to | 11484 crore in FY16-20. The current market price of. Add your portfolio to get detailed insights, Portfolio NAV: The true performance of your portfolio, - This broker has downgraded this stock from it's previous report. The company will utilise proceeds to reduce debt and other new strategic initiatives. Avenue Supermart 3,286.10 107.4. ARBP should complete the CAPA at Unit 7 soon. 559.07 . The company was founded by Penaka Venkata Ramprasad Reddy and Kambam Nithyananda Reddy on December 26, 1986 and is … And over the last one year, AUROPHARMA Share price change is about -8.23%. Hence, this transaction values the business at 3.5x sales, a compelling deal by any standards. Buy above. Aurobindo Pharm share price live updates on The Economic Times. EBITDA at Rs13,686mn (down 4.5% QoQ) and net profit at Rs29,465mn were in line with estimates. (2 new), MTAR Technologies' pricey IPO is a sign of our times, CIL approves 32 mining projects involving incremental investment of 47K crore, Results Declared in Last Two Days with both YoY and QoQ Profit Growth, MFs for your child's education or retirement, Create your own screener (from 1000+ indicators), Shareholding screeners for promoters, MFs, institutions, Just getting started? First down price target. Other business segments (ARV, API and Emerging Markets) were weaker and declined in low teens QoQ. Easy Trip Planners IPO to open today. Despite calling off acquisition of Sandoz' US dermatology, oral solid portfolio, sale of Natrol business, we expect US revenue to reach | 13661 crore in FY23E at 6% CAGR... Natrol had annual sales of US$157 million (4.8% of consolidated sales) in FY20. Adjusting for certain one-off exceptional items, Q3 results were in line with I-direct estimates on all fronts. The balance sheet is further strengthened as it turned net debt free as of Dec20. NSE Gainer-Large Cap . Management also guided for strong growth outlook (~20%) for the generic injectables business (~11% of revenues) over the next three years. Aurobindo Pharma Ltd., incorporated in the year 1986, is a Large Cap company (having a market cap of Rs 54796.98 Crore) operating in Pharmaceuticals sector. A combination of factors, including a sturdy new product pipeline, easing of pricing pressures, opportunities arising from shortage of products in the US, and an expected recovery in the injectable business would be key drivers for the US business.... Aurobindo Pharma Limited (ARBP) manufactures generic pharmaceuticals and active pharmaceutical ingredients. Copyright © 2021 Bennett, Coleman & Co. Ltd. All rights reserved. Over the Last one week Aurobindo Pharma Limited share price change is about 3.34%. The 45 reports from 11 analysts offering long term price targets ×. - Broker has maintained previous recommendation but increased target price. Add to watchlist. Sell below. Aurobindo Pharma Ltd.. captures the information on Price and Volume for a user defined time interval. Over the last 30 days, the price change is about 6.72%. The company was founded by Penaka Venkata Ramprasad Reddy and Kambam Nithyananda Reddy on December 26, 1986 and is … NSE Gainer-Large Cap . NSE -0.61 % is Rs 953.85. Sharekhan retains their Buy recommendation on Aurobindo Pharma with a revised Price target of Rs 1100. Should you subscribe? for Aurobindo Pharma Ltd. have an average target of 1048.82. Aurobindo pharma cmp 885.90 Buy above 892 for tgt of 920-940-970 SL 840 It is just a view trade with your own risk. Aurobindo Pharma Ltd. engages in the manufacturing of generic pharmaceuticals and active pharmaceutical ingredients. Get detailed Aurobindo Pharm stock price news and analysis, Dividend, Bonus Issue, Quarterly results information, and more. Aurobindo Pharma Share price: Sharekhan retains their Buy recommendation with a revised Price target of Rs 1100 Nifty to Sensex - All you need to know about markets today Key Covid-19 vaccines India banking on-Oxford/AstraZeneca, Novavax | Credit Suisse highlights Aurobindo Pharma, Apollo Hospitals stocks
Invisible Fence Batteries Canada, The Dark Pictures Games, Worldpay Safer Payments Login, Invisible Fence Break, Endefen For Acid Reflux, Terracotta Roof Shingles, Kacang Almond Harga, Jubilee Processing Plant,